bullish
Terumo Corp (4543 JP): H1FY23 Results Reflect Continued Recovery from the Pandemic
358 Views14 Dec 2022 18:40
SUMMARY
- Terumo Corp (4543 JP) recorded double-digit revenue growth in H1FY23, with record-high Q2 revenue exceeding ¥200 billion. All three businesses of Terumo reported growth during H1FY23.
- Cardiac and vascular segment remained the key growth driver and grew 21%, driven by a 24% y/y growth in overseas revenue amid the recovery and growth of medical demand.
- Inflation and normalization of sales and marketing activities impacted the profitability of the company. To improve profitability Terumo has taken further price increase in second half.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
- Terumo Corp (4543 JP): Record High Revenue and OP in H1FY24; Better Profitability Expected in H2FY2415 Nov 2023
- Terumo Corp (4543 JP): Strong C&V Business Momentum Continues; Profitability to Improve in FY2425 Jul 2023
- Terumo Corp (4543 JP): Sequential Decline Expected in Q4; Stronger Yen to Weigh on Performance28 Mar 2023
- Terumo Corp (4543 JP): H1FY23 Results Reflect Continued Recovery from the Pandemic14 Dec 2022
- Terumo Corp (4543 JP): A COVID Recovery Play; Cardiac & Vascular Business to Drive Multi-Year Growth26 Jul 2022
- Japan's Governance: Growth Policy and Corporate Governance of Terumo Corporation (4543)08 Nov 2021
x